Although the predisposition of Th2 CD4+ T cells in tumor have been implicated in BCG failure [17], the precise contribution of intratumoral CD8+ T cells in influencing the therapeutic efficacy of BCG remains largely elusive. The gene discussed is CD4; the disease is neoplasm.